Regencell Bioscience Holdings Limited (NASDAQ:RGC - Get Free Report) shot up 24.2% on Wednesday . The stock traded as high as $18.41 and last traded at $16.98. 1,755,281 shares were traded during trading, a decline of 86% from the average session volume of 12,884,282 shares. The stock had previously closed at $13.67.
Regencell Bioscience Stock Performance
Institutional Investors Weigh In On Regencell Bioscience
An institutional investor recently bought a new position in Regencell Bioscience stock. Greenfield Savings Bank bought a new stake in shares of Regencell Bioscience Holdings Limited (NASDAQ:RGC - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 11,000 shares of the company's stock, valued at approximately $187,000. Institutional investors own 0.13% of the company's stock.
Regencell Bioscience Company Profile
(
Get Free Report)
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder.
Featured Stories
Before you consider Regencell Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regencell Bioscience wasn't on the list.
While Regencell Bioscience currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access